JPWO2020012422A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020012422A5 JPWO2020012422A5 JP2021500532A JP2021500532A JPWO2020012422A5 JP WO2020012422 A5 JPWO2020012422 A5 JP WO2020012422A5 JP 2021500532 A JP2021500532 A JP 2021500532A JP 2021500532 A JP2021500532 A JP 2021500532A JP WO2020012422 A5 JPWO2020012422 A5 JP WO2020012422A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disorder
- methyl
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 65
- 208000035475 disorder Diseases 0.000 claims 58
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 24
- 208000028017 Psychotic disease Diseases 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 206010012289 Dementia Diseases 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 208000010877 cognitive disease Diseases 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 208000019116 sleep disease Diseases 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229920002401 polyacrylamide Polymers 0.000 claims 9
- 208000019901 Anxiety disease Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 6
- 208000029560 autism spectrum disease Diseases 0.000 claims 6
- 230000003542 behavioural effect Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000001568 sexual effect Effects 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 208000011117 substance-related disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 4
- 208000020706 Autistic disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims 4
- 230000005856 abnormality Effects 0.000 claims 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- 230000001066 destructive effect Effects 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 231100000872 sexual dysfunction Toxicity 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 3
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 claims 3
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 claims 3
- 239000002439 beta secretase inhibitor Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 229960004502 levodopa Drugs 0.000 claims 3
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- -1 1-methyl-1H-indole-5-yl Chemical group 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 2
- 208000036640 Asperger disease Diseases 0.000 claims 2
- 201000006062 Asperger syndrome Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- 208000030663 Libido disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000003863 Marijuana Abuse Diseases 0.000 claims 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010040981 Sleep attacks Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 2
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 2
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000028505 alcohol-related disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000561 anti-psychotic effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000001272 neurogenic effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000024309 orgasm disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 208000007100 phencyclidine abuse Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 2
- 208000015891 sexual disease Diseases 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- JJQQOTDMHDOYTF-UHFFFAOYSA-N (1,2-dimethylpyrrolo[2,3-b]pyridin-5-yl)methanamine Chemical compound CN1C(=CC=2C1=NC=C(C=2)CN)C JJQQOTDMHDOYTF-UHFFFAOYSA-N 0.000 claims 1
- BESDAEWBKZKOOE-UHFFFAOYSA-N (3-bromo-1-methylpyrrolo[2,3-b]pyridin-5-yl)methanamine Chemical compound BrC1=CN(C2=NC=C(C=C21)CN)C BESDAEWBKZKOOE-UHFFFAOYSA-N 0.000 claims 1
- UNOXCWIALZCQIP-UHFFFAOYSA-N (3-chloro-1-methylpyrrolo[2,3-b]pyridin-5-yl)methanamine Chemical compound Cn1cc(Cl)c2cc(CN)cnc12 UNOXCWIALZCQIP-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- SWISCHSCULZVBC-UHFFFAOYSA-N 6-chloro-N-[(1-methylindol-5-yl)methyl]-4-oxospiro[3H-chromene-2,3'-azetidine]-1'-carboxamide Chemical compound ClC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=2C=C3C=CN(C3=CC=2)C)=O)C=1 SWISCHSCULZVBC-UHFFFAOYSA-N 0.000 claims 1
- FYMWXTXPAIVRIU-UHFFFAOYSA-N CC=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=C(C=C3)C(F)(F)F)C1 Chemical compound CC=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=C(C=C3)C(F)(F)F)C1 FYMWXTXPAIVRIU-UHFFFAOYSA-N 0.000 claims 1
- XDXRTNDNZZFDPW-UHFFFAOYSA-N CC=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)C(F)(F)F)C1 Chemical compound CC=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)C(F)(F)F)C1 XDXRTNDNZZFDPW-UHFFFAOYSA-N 0.000 claims 1
- UYEQFCNSGDUMDF-UHFFFAOYSA-N CN1C2=CC=C(CN(C3)CC3(C=CC3=C4)OC3=CC=C4F)C=C2C=C1 Chemical compound CN1C2=CC=C(CN(C3)CC3(C=CC3=C4)OC3=CC=C4F)C=C2C=C1 UYEQFCNSGDUMDF-UHFFFAOYSA-N 0.000 claims 1
- MWNJXFIAACDEME-UHFFFAOYSA-N CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)C(F)(F)F)C1 Chemical compound CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)C(F)(F)F)C1 MWNJXFIAACDEME-UHFFFAOYSA-N 0.000 claims 1
- UAIAFALLOOCOLU-UHFFFAOYSA-N CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC=C3)C1 Chemical compound CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC=C3)C1 UAIAFALLOOCOLU-UHFFFAOYSA-N 0.000 claims 1
- FHTYNQSAWQBFCJ-UHFFFAOYSA-N CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(CC2)C=CC=C3)C1 Chemical compound CN1C=CC2=CC(=CC=C12)CNC(=O)N1CC2(OC3=C(CC2)C=CC=C3)C1 FHTYNQSAWQBFCJ-UHFFFAOYSA-N 0.000 claims 1
- SYIGSYZHPVPXFO-UHFFFAOYSA-N ClC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C=C1 Chemical compound ClC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C=C1 SYIGSYZHPVPXFO-UHFFFAOYSA-N 0.000 claims 1
- GZOXYFYONVZWEP-UHFFFAOYSA-N ClC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)Cl)=O)C=C1 Chemical compound ClC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)Cl)=O)C=C1 GZOXYFYONVZWEP-UHFFFAOYSA-N 0.000 claims 1
- JVJOJUFXXRLBMY-UHFFFAOYSA-N ClC1=CN(C2=CC=C(C=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=C(C=C3)F)C1)C Chemical compound ClC1=CN(C2=CC=C(C=C12)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=C(C=C3)F)C1)C JVJOJUFXXRLBMY-UHFFFAOYSA-N 0.000 claims 1
- KKUQUOFOARSXHE-UHFFFAOYSA-N ClC=1C=C(C2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1)Cl Chemical compound ClC=1C=C(C2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1)Cl KKUQUOFOARSXHE-UHFFFAOYSA-N 0.000 claims 1
- KCARFBWKQQCTET-UHFFFAOYSA-N ClC=1C=CC2=C(C(CC3(CCN(CC3)C(=O)NCC=3C=C4C=CN(C4=CC3)C)O2)=O)C1 Chemical compound ClC=1C=CC2=C(C(CC3(CCN(CC3)C(=O)NCC=3C=C4C=CN(C4=CC3)C)O2)=O)C1 KCARFBWKQQCTET-UHFFFAOYSA-N 0.000 claims 1
- MYGRYJMCQRUWMV-UHFFFAOYSA-N ClC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1 Chemical compound ClC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1 MYGRYJMCQRUWMV-UHFFFAOYSA-N 0.000 claims 1
- BOSAJEGQQIJOKE-UHFFFAOYSA-N ClC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=CNC2=CC3)=O)C1 Chemical compound ClC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=CNC2=CC3)=O)C1 BOSAJEGQQIJOKE-UHFFFAOYSA-N 0.000 claims 1
- LYEGTJOUTVMGGM-UHFFFAOYSA-N FC(C=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)F)C1)F Chemical compound FC(C=1NC2=CC=C(C=C2C1)CNC(=O)N1CC2(OC3=C(C(C2)=O)C=CC(=C3)F)C1)F LYEGTJOUTVMGGM-UHFFFAOYSA-N 0.000 claims 1
- YAENGOXVNACGGL-UHFFFAOYSA-N FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C(F)(F)F)=O)C=C1 Chemical compound FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C(F)(F)F)=O)C=C1 YAENGOXVNACGGL-UHFFFAOYSA-N 0.000 claims 1
- WDQXYXPAEPKMSA-UHFFFAOYSA-N FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C=C1 Chemical compound FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C=C1 WDQXYXPAEPKMSA-UHFFFAOYSA-N 0.000 claims 1
- LXOXUGXUUINWLS-UHFFFAOYSA-N FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=CN(C2=CC3)C)=O)C=C1 Chemical compound FC1=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=CN(C2=CC3)C)=O)C=C1 LXOXUGXUUINWLS-UHFFFAOYSA-N 0.000 claims 1
- CUKVZAWHRNNHFS-UHFFFAOYSA-N FC=1C=C(C2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1)F Chemical compound FC=1C=C(C2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1)F CUKVZAWHRNNHFS-UHFFFAOYSA-N 0.000 claims 1
- COBVBBSZLRJQHS-UHFFFAOYSA-N FC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1 Chemical compound FC=1C=CC2=C(C(CC3(O2)CN(C3)C(=O)NCC=3C=C2C=C(NC2=CC3)C)=O)C1 COBVBBSZLRJQHS-UHFFFAOYSA-N 0.000 claims 1
- HJQGJYHJSNIXEE-UHFFFAOYSA-N FC=1C=CC2=C(CCC3(O2)CN(C3)C(=O)NCC=3C=C2C=CN(C2=CC3)C)C1 Chemical compound FC=1C=CC2=C(CCC3(O2)CN(C3)C(=O)NCC=3C=C2C=CN(C2=CC3)C)C1 HJQGJYHJSNIXEE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1800248A HU231333B1 (hu) | 2018-07-13 | 2018-07-13 | Spirokromán származékok |
| HUP1800248 | 2018-07-13 | ||
| PCT/IB2019/055948 WO2020012422A1 (en) | 2018-07-13 | 2019-07-12 | Spirochromane derivatives |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531260A JP2021531260A (ja) | 2021-11-18 |
| JP2021531260A5 JP2021531260A5 (https=) | 2022-07-20 |
| JPWO2020012422A5 true JPWO2020012422A5 (https=) | 2022-07-20 |
| JP7487167B2 JP7487167B2 (ja) | 2024-05-20 |
Family
ID=89992725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500532A Active JP7487167B2 (ja) | 2018-07-13 | 2019-07-12 | スピロクロマン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20210330650A1 (https=) |
| EP (1) | EP3820869B1 (https=) |
| JP (1) | JP7487167B2 (https=) |
| KR (1) | KR20210033002A (https=) |
| CN (1) | CN112823157B (https=) |
| AR (1) | AR115782A1 (https=) |
| AU (1) | AU2019300514B2 (https=) |
| BR (1) | BR112020026996A2 (https=) |
| CA (1) | CA3104258A1 (https=) |
| CL (1) | CL2021000080A1 (https=) |
| CO (1) | CO2021001216A2 (https=) |
| CU (1) | CU24680B1 (https=) |
| EA (1) | EA202190245A1 (https=) |
| ES (1) | ES2964617T3 (https=) |
| GE (2) | GEAP202315557A (https=) |
| HU (2) | HU231333B1 (https=) |
| IL (1) | IL279938B2 (https=) |
| MX (1) | MX2021000460A (https=) |
| MY (1) | MY206779A (https=) |
| PE (1) | PE20211809A1 (https=) |
| PH (1) | PH12020552183A1 (https=) |
| SG (1) | SG11202012594RA (https=) |
| TW (1) | TWI821321B (https=) |
| WO (1) | WO2020012422A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| CN115403579A (zh) * | 2021-05-27 | 2022-11-29 | 上海拓界生物医药科技有限公司 | 一种新的螺环衍生物及其用途 |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2025175249A1 (en) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016548A1 (ja) | 2004-08-09 | 2006-02-16 | Eisai R & D Management Co., Ltd. | ヘテロ環化合物を含有する新規な抗マラリア剤 |
| NZ566036A (en) | 2005-09-13 | 2010-06-25 | Janssen Pharmaceutica Nv | 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor |
| CN101490056A (zh) * | 2006-05-17 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 烟碱乙酰胆碱受体的配体101 |
| TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| US20100298314A1 (en) | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| MX2010003156A (es) | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de aril amida substituida con tetrazol y usos de los mismos. |
| MX2010003155A (es) | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de ciclopropil aril amida y uso de los mismos. |
| KR20100124272A (ko) | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
| AR070936A1 (es) | 2008-03-19 | 2010-05-12 | Janssen Pharmaceutica Nv | 1,2,4 -triazoles trisustituidos |
| EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| WO2009127678A1 (en) * | 2008-04-17 | 2009-10-22 | Glaxo Group Limited | Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71 |
| JP5486591B2 (ja) | 2008-05-09 | 2014-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アセチルコリン受容体モジュレーターとしての三置換ピラゾール |
| CA2725940A1 (en) | 2008-05-30 | 2009-12-23 | Merck Sharp & Dohme Corp. | Novel substituted azabenzoxazoles |
| EP3795573B1 (en) | 2009-12-31 | 2022-07-06 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| WO2012042915A1 (en) | 2010-10-01 | 2012-04-05 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists |
| US9617210B2 (en) * | 2013-03-13 | 2017-04-11 | Lupin Limited | Pyrrole derivatives as alpha 7 NACHR modulators |
| AR107928A1 (es) | 2016-03-22 | 2018-06-28 | Merck Sharp & Dohme | Moduladores alostéricos de receptores de acetilcolina nicotínicos |
| US10870630B2 (en) | 2016-11-01 | 2020-12-22 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| WO2018112204A1 (en) * | 2016-12-14 | 2018-06-21 | Cephalon, Inc. | Spiropiperidine derivatives |
-
2018
- 2018-07-13 HU HUP1800248A patent/HU231333B1/hu unknown
-
2019
- 2019-06-27 TW TW108122548A patent/TWI821321B/zh active
- 2019-07-12 CA CA3104258A patent/CA3104258A1/en active Pending
- 2019-07-12 US US17/259,972 patent/US20210330650A1/en not_active Abandoned
- 2019-07-12 CU CU2020000108A patent/CU24680B1/es unknown
- 2019-07-12 AU AU2019300514A patent/AU2019300514B2/en not_active Ceased
- 2019-07-12 IL IL279938A patent/IL279938B2/en unknown
- 2019-07-12 WO PCT/IB2019/055948 patent/WO2020012422A1/en not_active Ceased
- 2019-07-12 PE PE2021000053A patent/PE20211809A1/es unknown
- 2019-07-12 KR KR1020217004264A patent/KR20210033002A/ko not_active Abandoned
- 2019-07-12 HU HUE19744868A patent/HUE064417T2/hu unknown
- 2019-07-12 GE GEAP202315557A patent/GEAP202315557A/en unknown
- 2019-07-12 JP JP2021500532A patent/JP7487167B2/ja active Active
- 2019-07-12 EA EA202190245A patent/EA202190245A1/ru unknown
- 2019-07-12 GE GEAP201915557A patent/GEP20237534B/en unknown
- 2019-07-12 BR BR112020026996-4A patent/BR112020026996A2/pt unknown
- 2019-07-12 EP EP19744868.1A patent/EP3820869B1/en active Active
- 2019-07-12 MY MYPI2020006684A patent/MY206779A/en unknown
- 2019-07-12 MX MX2021000460A patent/MX2021000460A/es unknown
- 2019-07-12 CN CN201980046665.7A patent/CN112823157B/zh active Active
- 2019-07-12 AR ARP190101991A patent/AR115782A1/es unknown
- 2019-07-12 SG SG11202012594RA patent/SG11202012594RA/en unknown
- 2019-07-12 ES ES19744868T patent/ES2964617T3/es active Active
-
2020
- 2020-12-16 PH PH12020552183A patent/PH12020552183A1/en unknown
-
2021
- 2021-01-12 CL CL2021000080A patent/CL2021000080A1/es unknown
- 2021-02-03 CO CONC2021/0001216A patent/CO2021001216A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531260A5 (https=) | ||
| JP6346658B2 (ja) | Ｍａｏ阻害剤としての置換ナフチリジン及びキノリン化合物 | |
| JP4198989B2 (ja) | セロトニン作動性薬 | |
| JP5947465B2 (ja) | Ｃｎｓ活性剤としてのベンズイミダゾール類 | |
| JP2011518801A (ja) | Ｎｋ３アンタゴニストとしてのイソキノリン誘導体 | |
| JP5538542B2 (ja) | 炭素環式ＧｌｙＴ１受容体アンタゴニスト | |
| JPWO2020212952A5 (https=) | ||
| JP2005535659A (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−１（ｎｋ−１）アンタゴニストとしての１−アミド−４−フェニル−４−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
| EP1682549B1 (en) | Imidazo[1,2-a]pyridine anxiolytics | |
| JP2016525142A (ja) | １，７−ナフチリジン誘導体 | |
| JPWO2020012422A5 (https=) | ||
| TW201033219A (en) | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | |
| JP2021529813A (ja) | チアジアジン誘導体 | |
| JP2011529477A (ja) | １，６−ジヒドロ−２ｈ−３−オキサ−６−アザ−ａｓ−インダセン化合物 | |
| JP3162523B2 (ja) | ピペリジルメチル−置換クロマン誘導体 | |
| IE922090A1 (en) | 2-(1-piperidyl)ethanol derivatives, their preparation and¹their therapeutic application | |
| JP2001522847A (ja) | ピペリジン誘導体およびそれらのタキキニン拮抗物質としての使用 | |
| EP1594864B1 (de) | Benzofuranoxyethylamine als antidepressiva und anxiolytika | |
| JP2021500323A (ja) | ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物 | |
| TW201206910A (en) | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | |
| JP2011026319A (ja) | 新規クロメン化合物、その製造方法、およびそれを含有する医薬組成物 | |
| JP2008503560A (ja) | ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト | |
| TW201206889A (en) | Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof | |
| JP2007186434A (ja) | 医薬組成物 | |
| TW201000101A (en) | New azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them |